EP 213: Inside the science of hearing loss and gene therapy for deafness with Ellen Reisinger of ...

Value of the Information & Strength of the Argument

The podcast provides valuable insights into the current state of gene therapy for hearing loss, particularly the scientific rationale behind targeting otoferlin. Reisinger’s explanations are clear and well-argued, drawing on her extensive research experience. She effectively communicates the advantages of otoferlin as a target, such as the preservation of hair cell structures and the non-degenerative nature of the condition, which makes postnatal treatment feasible. The discussion also critically evaluates the challenges of other genetic targets, such as GJB2, and the limitations of current animal models. The argumentation is solid, with Reisinger distinguishing between established knowledge and her personal opinions, such as her skepticism about prenatal gene therapy. The episode offers a balanced view of the field’s progress and obstacles, making it valuable for both scientists and informed laypeople.

Scientific Rigor, Source Quality, Title Accuracy

The scientific rigor is high, as Reisinger is a leading expert in the field, and her statements align with published research on otoferlin gene therapy. However, the podcast does not cite specific studies or provide direct references, which limits the ability to verify claims independently. The title accurately reflects the content, focusing on the science of hearing loss and gene therapy. The description includes a link to show notes, which may contain additional resources, but no specific sources are mentioned in the episode itself. The discussion is well-structured and technically accurate, though it would benefit from explicit citations to enhance its scholarly value.

The title accurately reflects the content, which focuses on hearing loss science and gene therapy, with Ellen Reisinger as the guest.

8/10

Expert with deep research background in otoferlin gene therapy; discussion grounded in published science, but no direct citations to specific papers; podcast format with personal opinions clearly distinguished.

• 00:00Intro to The Genetics Podcast
• 00:59Welcome to Ellen
• 01:52Ellen’s career path that coincidentally led to her work on otoferlin-related hearing loss
• 03:22Mechanism and advantages of the dual adenoassociated virus (AAV) system
• 05:35The genetic landscape of early-onset hearing loss and why otoferlin stands out
• 07:42Why otoferlin-related deafness is an ideal target for postnatal gene therapy development
• 09:53Potential next gene therapy targets beyond otoferlin and associated challenges
• 13:13Carrier and newborn screening as approaches to preventing hereditary hearing loss
• 14:37How far the field is from prenatal gene therapy and why it remains unlikely in the near term
• 16:07Exploring gene-agnostic and protective approaches to prevent or slow hearing loss
• 18:22How genetics and environment interact in age-related hearing loss
• 20:00Current research focus of Ellen’s group on degenerative hearing loss genes and uncovering cell death mechanisms
• 22:05Using mouse models and human organoids to study hearing loss mechanisms
• 23:42Emerging gene editing approaches
• 25:20Ellen’s research journey from biochemistry to leading gene therapy research in hearing loss
• 27:54Unanswered questions about how inner hair cells release neurotransmitters
• 29:21Comparing outcomes of gene therapy and cochlear implants for hearing restoration and differences across languages
• 34:20Closing remarks

• Show notes — Referenced in the video description as show notes for the episode.

• Otoferlin gene therapy clinical trial — Recent clinical trial results for otoferlin gene therapy, supporting the discussion.